US2019359577A1PendingUtilityA1
[4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1h-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof
Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: Aug 25, 2015Filed: Aug 6, 2019Published: Nov 28, 2019
Est. expiryAug 25, 2035(~9.1 yrs left)· nominal 20-yr term from priority
C07D 403/12A61K 31/498A61P 29/00A61P 27/02C07D 241/44A61K 31/675A61K 31/5377C07F 9/650994
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
Claims
exact text as granted — not AI-modified1 . A compound of
(S)-7-[4-[2-(N,N-dimethylaminoacetoxy)propyl]oxy-2-methoxyphenyl]-8-(5-fluoro-2-methylphenoxymethyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one,
or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.
2 . A compound of
(R)-7-[4-[2-(N,N-dimethylaminoacetoxy)propyl]oxy-2-methoxyphenyl]-8-(5-fluoro-2-methylphenoxymethyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one,
or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.
3 . A compound of
(S)-7-[4-(2-aminoacetoxypropyl)oxy-2-methoxyphenyl]-8-(5-fluoro-2-methyl-phenoxymethyl)-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one,
or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.
4 . A compound of
(S)-8-(5-fluoro-2-methylphenoxymethyl)-7-[4-(2-phosphonohydroxypropyl)oxy-2-methoxyphenyl]-1,3,3-trimethyl-3,4-dihydro-1H-quinoxalin-2-one,
or a pharmaceutically acceptable salt or a hydrate or a solvate thereof.Join the waitlist — get patent alerts
Track US2019359577A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.